Pioglitazone
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| + | <applet load="" size="480" color="" frame="true" spin="on" Scene ="'Pioglitazone/Pioglitazone/1" align="right" caption="Pioglitazone, also known as Actos"/> | ||
===Better Known as: Actos=== | ===Better Known as: Actos=== | ||
* Marketed By: Takeda Pharmaceuticals<br /> | * Marketed By: Takeda Pharmaceuticals<br /> | ||
Revision as of 09:20, 11 November 2010
|
Better Known as: Actos
- Marketed By: Takeda Pharmaceuticals
- Major Indication: Hypoglycemia & Type 2 Diabetes
- Drug Class: PPAR-γ Activator - Thiazolidinedione (Glitazones)
- Date of FDA Approval (Patent Expiration): 1999 (2011)
- 2009 Sales: $2.4 Billion [1]
- Why You Should Care: It is the best selling drug to treat Diabetes and is the 10th best selling drug in the United States.
- The following is a list of Pharmacokinetic Parameters. See: Pharmaceutical Drugs for more information
References
